These findings demonstrate an indispensable role for AXL in facilitating SARS‐CoV‐2 infection, suggesting combination treatments comprised of ACE2 and AXL inhibitors may be potentially efficacious therapeutic solutions for COVID‐19. This evidence concerns the gene ACE2 and COVID-19.